Page 1

UCB VIRTUAL CAPITAL MARKETS CALL Strengthening the evidence for the long - term benefits of BIMZELX® in hidradenitis suppurativa ( HS ) - EADV 2026 1 October 2026 ucb Inspired by patients . Driven by science . INTENDED FOR FINANCIAL ANALYSTS AND INSTITUTIONAL INVESTORS